Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Instagram Outage Disrupts Thousands of U.S. Users 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
 - EconoTimes)
NEW ORLEANS, Aug. 11, 2017 -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until September 29, 2017 to file lead plaintiff applications in a securities class action lawsuit against IntelliPharmaCeutics International, Inc. (NasdaqCM:IPCI), if they purchased the Company’s shares between January 14, 2016 and July 26, 2017, inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of New York.
Get Help
IntelliPharmaCeutics investors should visit us at https://www.claimsfiler.com/cases/view-intellipharmaceutics-international-inc-securities-litigation or call to speak to our claim center toll-free at (844) 367-9658.
About the Lawsuit
IntelliPharmaCeutics and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
The alleged false and misleading statements and omissions include, but are not limited to, that: (i) the Company failed to perform human abuse testing to support the New Drug Application (“NDA”) for Rexista; (ii) the Company failed to include studies conducted to support Rexista’s label claims regarding human abuse by various pathways; (iii) the Company was not submitting data to sufficiently support approval of the NDA; and (iv) as a result of the foregoing, IntelliPharmaCeutics’ financial statements were materially false and misleading at all relevant times.
About ClaimsFiler
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. ClaimsFiler's team of experts monitor the securities class action landscape and cull information from a variety of sources to ensure comprehensive coverage across a broad range of financial instruments.
To learn more about ClaimsFiler, visit www.claimsfiler.com.
